Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-05 · 397 (5) · 3477-3491
DOI: 10.1007/s00210-023-02825-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 15.11.2023. Verfasst von Marten A Khosravi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625, Hannover, Germany. Hauptthemen laut MEDLINE: Biological Availability, Clinical Trials as Topic, Curcumin, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Curcumin is an ingredient of the root Curcuma longa , which is responsible for the characteristic yellow color of curcuma. Curcumin is said to have the potential ability to fight malignant diseases and to have an anti-inflammatory effect. In addition, it is used as a dietary supplement. However, one problem with the use of curcumin is its extremely low bioavailability. The aim of this study is to systematically review and critically analyze clinical studies related to the pharmacokinetics (or bioavailability) and to the use of curcumin in the treatment of malignant diseases. The platforms clinicaltrials.gov and PubMed served as the database for the literature research. A total of 293 available studies on curcumin were filtered according to their focus (bioavailability, therapy of malignant diseases) and other criteria (study results, main substance, topic reference, existing disease/other research purpose, reference to malignant diseases). The studies were further analyzed regarding their outcome measures, their design (number of participants, randomization, placebo group, masking, ethical standards, sponsor, primary outcome measures, secondary outcome measures, study bias) and their findings. The analysis failed to convincingly demonstrate that curcumin has a significant, positive effect on the therapy of malignant diseases. Regarding the increase in bioavailability, positive results have been obtained, which are in proximity to the pharmaceutical industry. Independent studies could not achieve increased bioavailability of curcumin. The available reviews in the literature also do not provide convincing evidence for the efficacy of curcumin. Thus, at the time being, the use of curcumin in malignant diseases is not justified scientifically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625, Hannover, Germany.
- Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625, Hannover, Germany. seifert.roland@mh-hannover.de.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Khosravi, M. A., & Seifert, R. (2024). Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(5), 3477-3491. https://doi.org/10.1007/s00210-023-02825-7
Vancouver
Khosravi MA, Seifert R. Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(5):3477-3491. doi:10.1007/s00210-023-02825-7
BibTeX
@article{Khosravi2024,
author = {Khosravi, Marten A and Seifert, Roland},
title = {Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
volume = {397},
number = {5},
pages = {3477--3491},
doi = {10.1007/s00210-023-02825-7}
}
EUVIMED